POINT Biopharma Global Inc

POINT Biopharma Global — Investor Presentation (November 2021)

41 slides from POINT Biopharma Global's investor presentation, Nov 19, 2021

  1. Slide 1: Accelerating Precision Medicine – November 2021

    Slide 1: Accelerating Precision Medicine – November 2021

    Accelerating Precision Medicine™ Nasdaq: PNT Accelerating Precision Medicine™ November 2021

  2. Slide 2: Forward-Looking Statements and Disclaimer

    Slide 2: Forward-Looking Statements and Disclaimer

    Accelerating Precision Medicine™ Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “us,” “POINT,” or the “Company” refer to POINT Biopharma Global Inc. This information contained in this presentation does not constitute or for

  3. Slide 3: POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals

    Slide 3: POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals

    Accelerating Precision Medicine™ POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals POINT’S MISSION Accelerating the discovery, development and global access to life changing radiopharmaceuticals POINT’S VISION Transforming lives touched by cancer INDUSTRY-LEADING PIPELI

  4. Slide 4: One of the most experienced teams in radiopharmaceutical development and manufacturing

    Slide 4: One of the most experienced teams in radiopharmaceutical development and manufacturing

    Accelerating Precision Medicine™ POINT has assembled one of the most experienced teams in the clinical development and manufacturing of radiopharmaceuticals DR. JOE MCCANN, PHD CEO & Co-Founder DR. NEIL FLESHNER, MD Chief Medical Officer & Co-Founder ALLAN SILBER Executive Chairman & Co-Founder BILL

  5. Slide 5: Radiopharmaceuticals as a precise and powerful tool for cancer treatment

    Slide 5: Radiopharmaceuticals as a precise and powerful tool for cancer treatment

    Accelerating Precision Medicine™ Radiopharmaceuticals offer unique qualities that make them a precise and powerful tool for the treatment of cancer MOLECULARLY TARGETED RADIATION A cancer’s biology cannot prevent radiation from damaging its DNA. Precisely delivering radiation directly to cancer cell

  6. Slide 6: Novel ligands expanding cancer indications treatable with radiopharmaceuticals

    Slide 6: Novel ligands expanding cancer indications treatable with radiopharmaceuticals

    Accelerating Precision Medicine™ Novel ligands are greatly expanding the number of cancer indications that can be treated with radiopharmaceuticals Radioligands enable the precise targeting of cancer by combining a radioisotope, a linker & a targeting moiety that seek cancer cells LINKER Radioligand

  7. Slide 7: New radioisotopes further enhancing radiopharmaceuticals' capabilities

    Slide 7: New radioisotopes further enhancing radiopharmaceuticals' capabilities

    Accelerating Precision Medicine™ New radioisotopes are further enhancing radiopharmaceuticals’ capabilities POINT leverages the unique properties of a variety of medical isotopes Isotope selection considerations include radiation type, energy emission, and half-life. Many modern radioisotopes can be

  8. Slide 8: Platform overcomes barriers to radioligand commercialization

    Slide 8: Platform overcomes barriers to radioligand commercialization

    Accelerating Precision Medicine™ POINT’s platform overcomes the barriers that have prevented radioligand commercialization MANUFACTURING ISOTOPE SUPPLY PROGRAMS There are currently no large-scale contract radiopharmaceutical manufacturing facilities POINT custom built its own facility Isotopes are a

  9. Slide 9: Manufacturing and supply chain are key success factors

    Slide 9: Manufacturing and supply chain are key success factors

    Accelerating Precision Medicine™ Manufacturing and supply chain are the key success factors: radiopharmaceuticals are made just-in-time with a useable life measured in days The Indianapolis, Indiana manufacturing facility is complete and is expected to be cleared for clinical shipments by the end of

  10. Slide 10: Exceptional isotope supply chain

    Slide 10: Exceptional isotope supply chain

    Accelerating Precision Medicine™POINT’s Facility POINT’s isotope supply chain is exceptional in the radiopharmaceutical industry 10 Internal Lu-177 production capability provides a COGS advantage and supply chain redundancy Redundant Ac-225 supply from partners with access to rare Thorium and Radium

  11. Slide 11: Positioned to be a leader in next-generation radiopharmaceuticals

    Slide 11: Positioned to be a leader in next-generation radiopharmaceuticals

    Accelerating Precision Medicine™ POINT is positioned to be a leader in next-generation radiopharmaceuticals POINT's CanSEEK™ has been sub-licensed from both Bach Biosciences and Avacta Life Sciences, which has branded the technology as pre | CISION™ (an Avacta trademark). *mCRPC: Metastatic castrate

  12. Slide 12: CanSEEK technology to improve precision and safety of radioligands

    Slide 12: CanSEEK technology to improve precision and safety of radioligands

    Accelerating Precision Medicine™ POINT is creating the future of radiopharmaceuticals with technologies like CanSEEK™, designed to improve the precision and safety of all radioligands Images are renderings, created for explanatory purposes only. The CanSEEKTM technology has been sub-licensed from bo

  13. Slide 13: Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC

    Slide 13: Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC

    Accelerating Precision Medicine™l i i i i i ™ 13 Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC r r

  14. Slide 14: PNT2002 PSMA-targeted therapy for mCRPC, a $3.4B market

    Slide 14: PNT2002 PSMA-targeted therapy for mCRPC, a $3.4B market

    Accelerating Precision Medicine™ PNT2002 is a PSMA-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), a $3.4B market • Every year in the U.S. 12,000 men are diagnosed with mCRPC and an additional 40,000 progress from earlier stages of the disease • PNT2002 uses the PSMA-I&

  15. Slide 15: PSMA is a clinically validated therapeutic target

    Slide 15: PSMA is a clinically validated therapeutic target

    Accelerating Precision Medicine™ Prostate specific membrane antigen (PSMA) is a clinically validated therapeutic target, ideal for prostate cancer therapy 1. Davis M. et al. 2005. PNAS 2. Ghosh A. et al. 2004. J. Cell. Biochem. 3. Pangalos MN. et al. 1999. J. Biol. Chem. 4. Hupe MC. et al. 2018. Fro

  16. Slide 16: PNT2002 Phase 3 study protocol for mCRPC

    Slide 16: PNT2002 Phase 3 study protocol for mCRPC

    Accelerating Precision Medicine™ PNT2002’s Phase 3 Study for mCRPC: The Protocol Study Evaluating Metastatic Castrate Resistant Prostate Cancer Using 177Lu-PNT2002 PSMA Therapy versus Abiraterone or Enzalutamide After Second-Line Hormonal Treatment (NCT04647526), a multi-center, open label, randomiz

  17. Slide 17: PNT2002 is de-risked with efficacy and safety in line with PSMA-617

    Slide 17: PNT2002 is de-risked with efficacy and safety in line with PSMA-617

    Accelerating Precision Medicine™ PNT2002 (PSMA-I&T) is de-risked with efficacy and safety in-line with PSMA-617 * No head-to-head trials have been conducted 1. Baum et al. J Nucl Med 2016;57:1006-1013 2. Sartor et al. N Engl J Med 2021 3. Kratochwil et al. J Nucl Med .2016 4. Zhang et al. J Nucl Med

  18. Slide 18: Randomization begun in Canada, with EU and US expansion

    Slide 18: Randomization begun in Canada, with EU and US expansion

    Accelerating Precision Medicine™ Randomization has begun in Canada, with EU and US expansion to expedite accrual l i i i i i ™ EU Expansion 4Q 2021 Present Dosimetry Data at Scientific Congress 1Q 2022 Anticipated Start of US Randomization 1Q 2022 – 2Q 2022 NDA Planning and FDA Engagements 2Q 2022 –

  19. Slide 19: Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

    Slide 19: Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

    Accelerating Precision Medicine™ Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer l i i i i i ™ 19

  20. Slide 20: PNT2003 is a somatostatin receptor targeted treatment for NETs

    Slide 20: PNT2003 is a somatostatin receptor targeted treatment for NETs

    Accelerating Precision Medicine™ PNT2003 is a somatostatin receptor targeted treatment for Neuroendocrine cancer (NETs) NETs are heterogeneous tumors that originate in neuroendocrine cells1 • PNT2003 uses the SSTR-targeted DOTA- TATE ligand, also utilized in Lutathera™, a radiopharmaceutical by Nova

  21. Slide 21: SSTRs are a validated target for NETs therapy

    Slide 21: SSTRs are a validated target for NETs therapy

    Accelerating Precision Medicine™ Somatostatin receptors (SSTRs) are a validated target for NETs therapy SSTRs are ideal targets for NET therapy: • Somatostatin analogs (SSAs) have been developed with anti-secretory and anti-proliferative effects for NET therapy4,5 • Randomized clinical trials with s

  22. Slide 22: PNT2003's reduced radiation safety burden vs Novartis' Lutathera

    Slide 22: PNT2003's reduced radiation safety burden vs Novartis' Lutathera

    Accelerating Precision Medicine™ PNT2003’s reduced radiation safety burden offers a significant opportunity for differentiation from Novartis’ DOTA-TATE Lutathera® The lutetium-177 used in PNT2003 does not contain long-lived radioactive impurities, resulting in simplified administration of the drug

  23. Slide 23: NETs is a large market opportunity with multiple regulatory pathways

    Slide 23: NETs is a large market opportunity with multiple regulatory pathways

    Accelerating Precision Medicine™ Neuroendocrine Tumors (NETs) is a large market opportunity; there are multiple potential regulatory pathways available to PNT2003 (DOTA-TATE) In 2020, Novartis’ DOTA-TATE (Lutathera®) generated sales of $445M5 in GEP-NETs (orphan drug exclusivity expires in 2025) US

  24. Slide 24: Programs: PNT2004 FAP-α Targeting Ligand for Multiple Tumor Types

    Slide 24: Programs: PNT2004 FAP-α Targeting Ligand for Multiple Tumor Types

    Accelerating Precision Medicine™ Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand for Multiple Tumor Types 24l i i i i i ™

  25. Slide 25: PNT2004 is a best-in-class FAP-α targeted radioligand

    Slide 25: PNT2004 is a best-in-class FAP-α targeted radioligand

    Accelerating Precision Medicine™ PNT2004 is a best-in-class fibroblast activation protein (FAP-α) targeted radioligand with potential for imaging and therapy An ideal radiopharmaceutical targets and is retained in tumors, while flushing out of tissues absent of the target quickly. Developed in colla

  26. Slide 26: FAP-α is a pan cancer target for imaging and therapy

    Slide 26: FAP-α is a pan cancer target for imaging and therapy

    Accelerating Precision Medicine™ FAP-α is a compelling pan cancer target for imaging and therapy that is found in >90% of epithelial tumors4 In cancer, Fibroblast Activation Protein-α (FAP) is highly expressed on cancer associated fibroblasts (CAFs)3, which drives tumor progression and resistance to

  27. Slide 27: 68Ga-PNT6555 biodistribution shows fast tumor targeting

    Slide 27: 68Ga-PNT6555 biodistribution shows fast tumor targeting

    Accelerating Precision Medicine™ PNT6555 is the lead of the PNT2004 program. 68Ga-PNT6555 biodistribution studies demonstrate fast tumor targeting with little accumulation in normal tissues Rapid renal clearance of excess compound and good tumor retention with low background in other organs. 68Ga-PN

  28. Slide 28: 177Lu-PNT6555 shows prolonged tumor retention and rapid normal tissue clearance

    Slide 28: 177Lu-PNT6555 shows prolonged tumor retention and rapid normal tissue clearance

    Accelerating Precision Medicine™ 177Lu-PNT6555 biodistribution studies demonstrate prolonged tumor retention and rapid normal tissue clearance Rapid and persistent tumor targeting beyond 7 days with low retention in normal tissues, with exquisite tumor / kidney ratio Organ uptake 177Lu-PNT6555 SPECT

  29. Slide 29: 177Lu/225Ac PNT6555 shows anti-tumor activity with long-term survival

    Slide 29: 177Lu/225Ac PNT6555 shows anti-tumor activity with long-term survival

    Accelerating Precision Medicine™ 177Lu/225Ac PNT6555 shows compelling anti-tumor activity, with mice experiencing long-term survival HEK-mFAP tumor bearing Fox Chase SCID, n=6/cohort 225Ac-PNT6555177Lu-PNT6555 6/6 tumor free 60MBq 3/6 tumor free 30MBq 4/6 tumor free 50kBq 29 0 10 20 30 40 50 60 70 8

  30. Slide 30: PNT2004 on track for IND/CTA submission in 1Q 2022

    Slide 30: PNT2004 on track for IND/CTA submission in 1Q 2022

    Accelerating Precision Medicine™ PNT2004 is on track for an IND/CTA Submission in the 1st quarter of 2022 Candidate selection complete. Additional studies in syngeneic and PDX models for monotherapy and combination treatment are in development Process and method optimization and validation ongoing w

  31. Slide 31: Programs: PNT2001 Next-Generation PSMA Targeting Ligand

    Slide 31: Programs: PNT2001 Next-Generation PSMA Targeting Ligand

    Accelerating Precision Medicine™ Programs: PNT2001 Next-Generation PSMA Targeting Ligand 31l i i i i i ™

  32. Slide 32: PNT2001 is a next-generation PSMA radioligand for Ac-225 and Lu-177

    Slide 32: PNT2001 is a next-generation PSMA radioligand for Ac-225 and Lu-177

    Accelerating Precision Medicine™ PNT2001 is a next-generation PSMA radioligand suited for delivery of Actinium-225 and Lutetium-177 1. Mehtälä J et al. PLOS ONE 2020 2. US Patent 16/765,729 3. American Cancer Association – Cancer Facts & Figures 2020 4. Surveillance, Epidemiology, and End Results (S

  33. Slide 33: PNT2001 linker technology increases internalization and tumor uptake

    Slide 33: PNT2001 linker technology increases internalization and tumor uptake

    Accelerating Precision Medicine™ PNT2001 has linker technology that allows for increased internalization into cells, resulting in increased tumor uptake Unpublished data NATLu-PNT2001 (n=3) Improved internalizationImproved affinity Improved tumor uptake 177LuPNT2001 PNT2001 IC50: 3.1nM PNT2002 IC50:

  34. Slide 34: Programs: CanSEEK FAP-α Activated Prodrug Technology Platform

    Slide 34: Programs: CanSEEK FAP-α Activated Prodrug Technology Platform

    Accelerating Precision Medicine™ 34l i i i i i ™ Programs: CanSEEK™ FAP-α Activated Prodrug Technology Platform

  35. Slide 35: Off-target delivery limits usage of next-generation radioisotopes

    Slide 35: Off-target delivery limits usage of next-generation radioisotopes

    Accelerating Precision Medicine™ Early Actinium–225 (Ac-225) clinical data demonstrates the off-target delivery is limiting usage of next-generation radioisotopes 1. Kratochwil, C, et al. J Nucl Med 2016 2. Zacherl, M, et al. J Nucl Med 2020 3. Ruigrok, E, et al. Pharmaceceutics 2019 3 cycles of 9-1

  36. Slide 36: CanSEEK prodrug technology activated by FAP-α

    Slide 36: CanSEEK prodrug technology activated by FAP-α

    Accelerating Precision Medicine™ …until it reaches FAP-α, which is present in >90% of epithelial tumor microenvironments1… The goal of the CanSEEK™ prodrug technology platform is to improve precision and safety of all radioligands CanSEEK™, currently in pre-clinical development, prevents a radioliga

  37. Slide 37: CanSEEK enables re-evaluation of known ligands

    Slide 37: CanSEEK enables re-evaluation of known ligands

    Accelerating Precision Medicine™ CanSEEK™ is as a radiopharmaceutical drug platform that enables re-evaluation of known ligands previously set aside due to off-target delivery concerns By extending the therapeutic index of ligands, CanSEEK™ could also enable the use of emerging medical isotopes like

  38. Slide 38: Summary & Milestones

    Slide 38: Summary & Milestones

    Accelerating Precision Medicine™ 38 Summary & Milestones ™

  39. Slide 39: Driving innovation by overcoming current limitations of radiopharmaceuticals

    Slide 39: Driving innovation by overcoming current limitations of radiopharmaceuticals

    Accelerating Precision Medicine™ POINT will drive innovation in radiopharmaceuticals by overcoming their current limitations Ligands suffer from off target delivery, limiting them to later stages of disease Isotopes cannot be used in large enough doses to cause complete tumor regression No radioliga

  40. Slide 40: Upcoming Milestones & Financial Summary

    Slide 40: Upcoming Milestones & Financial Summary

    Accelerating Precision Medicine™ Upcoming Milestones & Financial Summary Timing (Est.) Program Clinical Candidate Indication Milestone 4Q 2021 Manufacturing 177Lu-PSMA I&T mCRPC IND Amendment to add facility to supply chain 1Q 2022 177Lu-PSMA I&T mCRPC Dosimetry lead-in presentation 177Lu-DOTA-TATE

  41. Slide 41: POINTBiopharma.com investors@pointbiopharma.com

    Slide 41: POINTBiopharma.com investors@pointbiopharma.com

    Accelerating Precision Medicine™ 41 Nasdaq: PNT POINTBiopharma.com investors@pointbiopharma.com

Source: SEC EDGAR · 8-K filed Nov 19, 2021

More decks from POINT Biopharma Global Inc